Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Amgen
Study ID
NCT07493512
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Xaluritamig — DRUG
    Participants will receive xaluritamig via short-term intravenous (IV) infusion.

Study Details

The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).

Key Dates

First listed
Mar 25, 2026
Start date
Apr 28, 2026
Status verified
Jun 2026
Primary completion
Jan 30, 2028
Completion
Jul 30, 2030

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Xaluritamig Proposed Regimen
    Participants will be dosed at the proposed regimen until disease progression or discontinuation of study treatment.

Primary Outcome Measure

Number of Participants with Treatment-emergent Adverse Events [ Time Frame: Up to 3.6 Year ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Thomas Jefferson UniversityPhiladelphiaPennsylvania19107-
University of Pittsburgh Medical Center Hillman Cancer CenterPittsburghPennsylvania15232-
Sanford Oncology Clinic and PharmacySioux FallsSouth Dakota57104-
Sarah Cannon Research Institute Oncology PartnersNashvilleTennessee37203-
Next Oncology - DallasIrvingTexas75039-

Find similar trials in Philadelphia, PA

By research site
Thomas Jefferson University· Philadelphia, PAUniversity of Pittsburgh Medical Center Hillman Cancer Center· Pittsburgh, PASanford Oncology Clinic and Pharmacy· Sioux Falls, SDSarah Cannon Research Institute Oncology Partners· Nashville, TNNext Oncology - Dallas· Irving, TX

Related Studies